These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21029745)

  • 1. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
    Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A
    Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.
    Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A
    Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
    Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
    J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
    Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
    Torii Y; Sasaki M; Shin MC; Akaike N; Kaji R
    Toxicon; 2018 Oct; 153():114-119. PubMed ID: 30193802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.
    Takeuchi T; Okuno T; Miyashiro A; Kohda T; Miyamoto R; Izumi Y; Kozaki S; Kaji R
    Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
    Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
    Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A.
    Yoneda S; Shimazawa M; Kato M; Nonoyama A; Torii Y; Nishino H; Sugimoto N; Kozaki S; Hara H
    Eur J Pharmacol; 2005 Jan; 508(1-3):223-9. PubMed ID: 15680275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat.
    Shin MC; Yukihira T; Ito Y; Akaike N
    Toxicon; 2013 Mar; 64():12-9. PubMed ID: 23270755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical differences between A1 and A2 botulinum toxin subtypes.
    Kaji R
    Toxicon; 2015 Dec; 107(Pt A):85-8. PubMed ID: 26394198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.
    Akaike N; Shin MC; Wakita M; Torii Y; Harakawa T; Ginnaga A; Kato K; Kaji R; Kozaki S
    J Physiol; 2013 Feb; 591(4):1031-43. PubMed ID: 23109108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.
    Kaji R; Miyashiro A; Sato N; Furumoto T; Takeuchi T; Miyamoto R; Kohda T; Izumi Y; Kozaki S
    Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses.
    Akaike N; Ito Y; Shin MC; Nonaka K; Torii Y; Harakawa T; Ginnaga A; Kozaki S; Kaji R
    Toxicon; 2010 Dec; 56(8):1315-26. PubMed ID: 20674584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins.
    Torii Y; Goto Y; Takahashi M; Ishida S; Harakawa T; Sakamoto T; Kaji R; Kozaki S; Ginnaga A
    Toxicon; 2010; 55(2-3):407-14. PubMed ID: 19778548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treadmill running upregulates the expression of acetylcholine receptor in rat gastrocnemius following botulinum toxin A injection.
    Tsai SW; Tung YT; Chen HL; Shen CJ; Chuang CH; Tang TY; Chen CM
    J Orthop Res; 2013 Jan; 31(1):125-31. PubMed ID: 22733692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose- and volume dependent-response to intramuscular injection of botulinum neurotoxin-A optimizes muscle force decrement in mice.
    Stone AV; Ma J; Callahan MF; Smith BP; Garrett JP; Smith TL; Koman LA
    J Orthop Res; 2011 Nov; 29(11):1764-70. PubMed ID: 21491479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved calcium utilization at motor nerve terminals exposed to botulinum neurotoxin in mice.
    Fujikawa R; Ishii T; Komori S; Nishimura M
    J Physiol Sci; 2008 Dec; 58(6):419-24. PubMed ID: 18845060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
    Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
    Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.
    Durham PL; Cady R; Cady R
    Headache; 2004 Jan; 44(1):35-42; discussion 42-3. PubMed ID: 14979881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of neuromuscular blockade and recovery with botulinum toxins A and F.
    Billante CR; Zealear DL; Billante M; Reyes JH; Sant'Anna G; Rodriguez R; Stone RE
    Muscle Nerve; 2002 Sep; 26(3):395-403. PubMed ID: 12210370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.